By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
PHARMA JOBS POSTPHARMA JOBS POSTPHARMA JOBS POST
  • HOME
  • FRESHERS
  • LOCATIONS
  • ABOUT US
  • CONTACT
  • DISCLAIMER
Notification
PHARMA JOBS POSTPHARMA JOBS POST
  • HOME
  • FRESHERS
  • LOCATIONS
  • ABOUT US
  • CONTACT
  • DISCLAIMER
Have an existing account? Sign In
Follow US
PHARMA JOBS POST © 2024 All Rights Reserved.
WhatsApp Group Join Now
Telegram Group Join Now
- Advertisement -
Ad imageAd image
Ad imageAd image
PHARMA JOBS POST > announcement > FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer
announcementColorectal cancer

FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer

RAJLAXMI
Last updated: May 8, 2025 6:21 pm
RAJLAXMI 3 weeks ago 133 Views
Share
SHARE

The Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for adult and pediatric patients 12 years of age and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC). The FDA also converted the accelerated approval to regular approval for single agent nivolumab for adult and pediatric patients 12 years of age and older with MSI-H or dMMR metastatic CRC, that has progressed following fluoropyrimidine, oxaliplatin, and irinotecan.

Full prescribing information for Opdivo and Yervoy will be posted on Drugs@FDA.

Efficacy and Safety;

Efficacy of nivolumab with ipilimumab was evaluated in CHECKMATE-8HW (NCT04008030), a randomized, three-arm, open-label trial in immunotherapy-naïve patients with unresectable or metastatic CRC with known MSI-H or dMMR status. Patients were randomized to receive one of the following treatments:

• nivolumab 240 mg every 3 weeks and ipilimumab 1 mg/kg every 3 weeks for a maximum of 4 doses, then nivolumab 480 mg every 4 weeks,

• nivolumab 240 mg every 2 weeks for 6 doses, then nivolumab 480 mg every 4 weeks, or
investigator’s choice chemotherapy:

The major efficacy outcome measure was progression-free survival (PFS) assessed by blinded independent central review (BICR) per RECIST v1.1 in patients with centrally confirmed MSI-H/dMMR status in the following pre-specified settings:

First-line setting: nivolumab + ipilimumab versus chemotherapy,
All lines: nivolumab + ipilimumab versus nivolumab alone.
The analysis of nivolumab + ipilimumab versus chemotherapy in the first line setting was conducted in 255 patients with centrally confirmed MSI-H/dMMR status of 303 patients based on local testing. Median PFS was not reached (NR) (95% CI: 38.4, not estimable [NE]) in the nivolumab + ipilimumab arm and 5.8 months (95% CI: 4.4, 7.8) in the chemotherapy arm (Hazard ratio 0.21 [95% CI: 0.14, 0.32] p-value <0.0001). Comparative results of ORR and OS between arms were not available at the time of the interim PFS analysis due to statistical testing strategy.

• First-line setting: nivolumab + ipilimumab versus chemotherapy,

• All lines: nivolumab + ipilimumab versus nivolumab alone.

The analysis of nivolumab + ipilimumab versus chemotherapy in the first line setting was conducted in 255 patients with centrally confirmed MSI-H/dMMR status of 303 patients based on local testing. Median PFS was not reached (NR) (95% CI: 38.4, not estimable [NE]) in the nivolumab + ipilimumab arm and 5.8 months (95% CI: 4.4, 7.8) in the chemotherapy arm (Hazard ratio 0.21 [95% CI: 0.14, 0.32] p-value <0.0001). Comparative results of ORR and OS between arms were not available at the time of the interim PFS analysis due to statistical testing strategy.

The analysis of nivolumab + ipilimumab versus nivolumab (all lines) was conducted in 582 patients with centrally confirmed MSI-H/dMMR status of 707 patients based on local testing. Median PFS was NR (95% CI: 53.8, NE) in the nivolumab + ipilimumab arm and 39.3 months (95% CI: 22.1, NE) in the nivolumab arm (Hazard ratio 0.62 [95% CI: 0.48, 0.81] p-value 0.0003). ORR was 71% (95% CI: 65, 76) in the nivolumab + ipilimumab arm and 58% (95% CI: 52, 63) in the nivolumab arm (p-value 0.0011). The comparative results of OS between arms were not available at the interim PFS analysis due to statistical testing strategy.

The most common adverse reactions reported in ≥20% of patients treated with nivolumab with ipilimumab were fatigue, diarrhea, pruritus, abdominal pain, musculoskeletal pain, and nausea. The most common adverse reactions reported in ≥20% of patients treated with nivolumab as a single agent were fatigue, diarrhea, abdominal pain, pruritis, and musculoskeletal pain.

WhatsApp Group Join Now
Telegram Group Join Now
- Advertisement -
DEFINE ACADEMY DRUG REGULATORY AFFAIRSDEFINE ACADEMY DRUG REGULATORY AFFAIRS
TAGGED: FDA, treatment
Share This Article
Facebook Twitter LinkedIn Email Print
Previous Article Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
Next Article Granules India Walk-In Interview on 14 May 2025 for API Production & SRS Roles

RECENT POSTS

  • Walk-In Interview at Aurobindo Pharma – Hiring for Production, QA, QC & Packing | 1st June 2025, Hyderabad
  • Macleods Pharma Hiring in Haridwar – Apply for Baddi & Sikkim Jobs (June 1, 2025)
  • Numandis Group Recruitment 2025 – FTE Department Hiring Freshers
  • Exciting QA & QC Job Openings at Wings Biotech
  • Career Opportunity: Production Roles at Venus Remedies
  • Walk-In Drive at OneSource (Arcolab) – Hiring for Biotech & Pharma Roles in Hyderabad | June 1, 2025
  • Walk-In Interview at Brooks Steriscience Vadodara – QC & Production Jobs (1st June 2025)
  • Vimta Careers: Walk-In Interview for Food Testing Roles – June 14
  • Walk-In Interview at Corona Remedies for ADL & QA Roles – 1st June 2025
  • R&D Careers at Apex Pharma – Formulation Specialist Wanted
  • FDA takes steps to enhance state importation programs to help lower prescription drug prices
  • MSN Laboratories Walk-In  on 1st June | QC, Microbiology & Production (Injectables) Jobs
  • Bharat Biotech Walk-In on 31st May for Production, Packing & Visual Inspection Jobs
JOIN WHATSAPP CHANNEL

Recent Jobs

  • Mylan Laboratories Limited

    Mylan Laboratories to Conduct Walk-In Interviews for Injectable Manufacturing Roles in Hosur

    • Hosur, Krishnagiri, Tamil Nadu
    • Mylan Laboratories Limited
  • Cadila Pharmaceuticals

    Pharma R&D Jobs: Analyst Vacancy in Analytical Research Laboratory (0–4 Years Exp) at Cadila Pharmaceuticals

    • Dholka, Ahmedabad
    • Cadila Pharmaceuticals
  • Lupin Biotech

    Lupin Biotech to Conduct Walk-in Interviews in Pune for QA, QC, and Biosimilars Roles

    • Pune, Maharashtra
    • Lupin Biotech
  • Ajanta Pharma Ltd.

    Ajanta Pharma Ltd Announces Walk-In Interviews for Multiple Roles at US FDA Approved Facility in Maharashtra

    • Chhatrapati Sambhajinagar
    • Ajanta Pharma Ltd.
  • Evertogen Lifesciences Ltd.

    Evertogen Lifesciences Ltd. Invites Fresh Talent to Join Its Team at Jadcherla Facility

    • Jadcherla
    • Evertogen Lifesciences Ltd.
  • Cadila Pharmaceuticals

    We’re Hiring: Research Associate / Sr. Research Associate – Formulation Development (Injectables)

    • Dholka, Ahmedabad
    • Cadila Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd.

    Sun Pharma – Dewas is Hiring: Wruster Coating Supervisor Wanted

    • Dewas, Madhya Pradesh
    • Sun Pharmaceutical Industries Ltd.
  • Biodeal Pharmaceuticals Ltd

    Biodeal Pharmaceuticals Ltd. is Hiring! Explore Career Opportunities in QC, R&D, and Production

    • Nalagarh
    • Biodeal Pharmaceuticals Ltd
  • Scientific Writing Jobs at Indegene – Open to Freshers and Experienced Candidates (0–2 Years)

    • Anywhere
  • IQVIA

    IQVIA is Hiring Freshers! Kickstart Your Consulting Career in Healthcare

    • Bengaluru, India
    • IQVIA
  • Biological E. Limited

    Biological E. Limited is hiring for Regulatory Affairs Department

    • Genome Valley, Shameerpet, Hyderabad
    • Biological E. Limited
  • Genedrift

    Genedrift is Hiring: Regulatory Affairs Roles Open (Entry & Senior Level)

    • Uttarakhand
    • Genedrift

Tags

Ahmedabad (65) ahmedabad pharma jobs (189) ahmedabad pharma vacancy (165) ahmedabad pharma walk in interview (89) Baddi Pharma Vacancy (59) Bangalore pharma company jobs (41) Bangalore pharma jobs (31) FRESHERS (181) freshers jobs in pharma industry (50) freshers pharmacy jobs (46) goa pharma company job (27) Hiring (119) Hiring jobs (458) Hyderabad (57) hyderabad pharma company jobs (184) hyderabad pharma jobs (94) hyderabad pharma jobs freshers (42) hyderabad pharma vacancies (111) hyd pharma jobs (31) indore pharma company vacancy (27) job alert (379) job Opportunity (246) Job search (457) job Vaccancy (447) Mumbai Pharma company jobs (34) Pharmacovigilance Jobs vacancy (38) Pharma jobs (104) Pharma jobs at Baddi (36) pharma jobs in hyderabad (84) Pharma QA Jobs (35) pharma qa vacancy (28) pharma vacancy in ahmedabad (30) pharma walk in interview (44) Production (58) Production Department (73) QA (53) QC (77) QC Department (45) Quality Control (QC) (32) Regulatory Affairs (55) Regulatory Affairs Jobs Vacancy (63) Vadodara (33) Vadodara Pharma Job Vacancy (53) Walk In Drive (125) Walk In Interview (180)
PHARMA JOBS POSTPHARMA JOBS POST
Follow US
PHARMA JOBS POST © 2024 All Rights Reserved.
JOIN OUR WHATSAPP GROUP
JOIN OUR TELEGRAM GROUP
Welcome Back!

Sign in to your account

Lost your password?